LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 620

Search options

  1. Book ; Online ; E-Book: Concise guide to neuropsychiatry and behavioral neurology

    Barry, John J. / Bajestan, Sepideh / Cummings, Jeffrey L. / Trimble, Michael R.

    2023  

    Author's details John J. Barry, Sepideh Bajestan, Jeeffrey L. Cummings, Michael R. Trimble
    Keywords Electronic books ; Brain Diseases / physiopathology ; Mental Disorders / diagnosis ; Mental Disorders / therapy ; Neuropsychology / methods
    Language English
    Size 1 Online-Ressource (xx, 397 Seiten), Illustrationen
    Edition Third edition
    Publisher American Psychiatric Association Publishing
    Publishing place Washington, DC
    Publishing country United States
    Document type Book ; Online ; E-Book
    Note Description based on publisher supplied metadata and other sources
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT021393450
    ISBN 978-1-61537-410-6 ; 9781615374090 ; 1-61537-410-8 ; 1615374094
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book: Alzheimer's disease drug development

    Cummings, Jeffrey L. / Kinney, Jefferson W. / Fillit, Howard

    research and development ecosystem

    2022  

    Author's details edited by Jeffrey Cummings, Jefferson Kinney, Howard Fillit
    Keywords Alzheimer's disease ; Drug development ; Drugs / Research ; Alzheimer's disease / Treatment ; Alzheimer Disease / drug therapy ; Drug Discovery
    Language English
    Size xx, 553 Seiten, Illustrationen, Diagramme, Karte
    Publisher Cambridge University Press
    Publishing place New York, NY
    Publishing country United States
    Document type Book
    HBZ-ID HT021389530
    ISBN 978-1-108-83866-5 ; 9781108975759 ; 1-108-83866-9 ; 1108975755
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article ; Online: "Landscape of Phase 2 Trials in Alzheimer's Disease": Perspective on Adaptive Trials.

    Cummings, Jeffrey

    Journal of Alzheimer's disease : JAD

    2024  Volume 98, Issue 3, Page(s) 859–861

    Abstract: Better means of conducting more efficient clinical trials for the development of Alzheimer's disease (AD) therapeutics are required. Adaptive clinical trial designs have many advantages based on the ability to make prespecified changes in the trial ... ...

    Abstract Better means of conducting more efficient clinical trials for the development of Alzheimer's disease (AD) therapeutics are required. Adaptive clinical trial designs have many advantages based on the ability to make prespecified changes in the trial conduct depending on the ongoing experience in the trial. In their report in the Journal of Alzheimer's Disease, Lee and colleagues show that in the past 25 years only 2.5% of AD clinical trials have used adaptive designs. The report calls attention to the opportunity to use adaptive designs more often in Phase 2 clinical trials to improve trial efficiency and accelerate treatment development.
    MeSH term(s) Humans ; Alzheimer Disease/drug therapy ; Research Design
    Language English
    Publishing date 2024-03-08
    Publishing country Netherlands
    Document type Clinical Trial, Phase II ; Journal Article
    ZDB-ID 1440127-7
    ISSN 1875-8908 ; 1387-2877
    ISSN (online) 1875-8908
    ISSN 1387-2877
    DOI 10.3233/JAD-240145
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book ; Online ; E-Book: Neuro-geriatrics

    Tousi, Babak / Cummings, Jeffrey L.

    a clinical manual

    2017  

    Author's details Babak Tousi, Jeffrey Cummings editors
    Language English
    Size 1 Online-Ressource (XXIV, 407 Seiten)
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019582542
    ISBN 978-3-319-56484-5 ; 9783319564838 ; 3-319-56484-6 ; 3319564838
    DOI 10.1007/978-3-319-56484-5
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  5. Book: Neurodegenerative diseases

    Cummings, Jeffrey L. / Pillai, Jagan

    unifying principles

    2017  

    Author's details edited by Jeffrey L. Cummings, Jagan A. Pillai
    Keywords Neurodegenerative Diseases
    Language English
    Size XI, 346 Seiten, Illustrationen
    Publisher Oxford University Press
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT019238039
    ISBN 978-0-19-023356-3 ; 0-19-023356-7
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Book: Effective and efficient diagnosis of Parkinsonism

    Cummings, Jeffrey L.

    the role of dopamine transporter SPECT imaging with ioflupane I-123 injection (DaTscan TM)

    (The American journal of managed care ; 20,5, Suppl.)

    2014  

    Author's details Jeffrey L. Cummings
    Series title The American journal of managed care ; 20,5, Suppl.
    Collection
    Language English
    Size S. S93 - S112 : Ill.
    Publisher Managed Care & Healthcare Communications
    Publishing place S.l.
    Publishing country United States
    Document type Book
    HBZ-ID HT018264144
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  7. Article ; Online: Rarer Dementias, Limited Options, and Unaddressed Needs.

    Cummings, Jeffrey

    International psychogeriatrics

    2023  , Page(s) 1–7

    Language English
    Publishing date 2023-05-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 1038825-4
    ISSN 1741-203X ; 1041-6102
    ISSN (online) 1741-203X
    ISSN 1041-6102
    DOI 10.1017/S1041610223000431
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.

    Cummings, Jeffrey

    Drugs

    2023  Volume 83, Issue 7, Page(s) 569–576

    Abstract: Two anti-amyloid monoclonal antibodies (MABs)-lecanemab ( ... ...

    Abstract Two anti-amyloid monoclonal antibodies (MABs)-lecanemab (Leqembi
    MeSH term(s) Humans ; Alzheimer Disease/drug therapy ; Antibodies, Monoclonal/therapeutic use
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2023-04-15
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 120316-2
    ISSN 1179-1950 ; 0012-6667
    ISSN (online) 1179-1950
    ISSN 0012-6667
    DOI 10.1007/s40265-023-01858-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary.

    Cummings, Jeffrey

    Alzheimer's & dementia (New York, N. Y.)

    2023  Volume 9, Issue 3, Page(s) e12411

    Abstract: Introduction: Approval of the anti-amyloid monoclonal antibodies has stimulated an important discussion of the value to be placed on the magnitude of slowing achieved by treatment compared to placebo.: Methods: The minimal clinically important ... ...

    Abstract Introduction: Approval of the anti-amyloid monoclonal antibodies has stimulated an important discussion of the value to be placed on the magnitude of slowing achieved by treatment compared to placebo.
    Methods: The minimal clinically important difference (MCID) was reviewed in the context of other measures and analyses that provide perspective on the meaningfulness of treatment responses.
    Results: TheMCID is a clinician-anchored approach to making this determination. The MCID applies best to symptomatic therapies for which the drug-placebo difference remains constant. Disease-modifying therapies produce a progressive divergence of drug and placebo trajectories; early in the course the MCID would not be achieved, later the MCID will be achieved, and with continuing therapy the MCID will be exceeded. Clinicians are not the only stakeholders involved in determining the value proposition of slowing disease progression. Patient-reported outcomes and caregiver-related measures offer important complementary insights. Analytic approaches also widen the perspective on the observed drug-placebo differences. Risk ratios, numbers needed to treat versus number needed to harm, time-to-event analyses, and predictive benefits based on biomarkers all add depth to the discussion.
    Discussion: Multiple stakeholder perspectives are needed to determine the importance to be attributed to the therapeutic changes observed with monoclonal antibody therapies and other emerging treatments.
    Language English
    Publishing date 2023-07-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2832891-7
    ISSN 2352-8737 ; 2352-8737
    ISSN (online) 2352-8737
    ISSN 2352-8737
    DOI 10.1002/trc2.12411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Book ; Online ; E-Book: Cognitive enhancement in CNS disorders and beyond

    Keefe, Richard S. / Reichenberg, Avraham / Cummings, Jeffrey L.

    2018  

    Author's details edited by Richard S.E. Keefe, PhD; Abraham Reichenberg, PhD; Jeffrey Cummings, MD, ScD
    Language English
    Size 1 Online-Ressource (xiv, 433 Seiten), Illustrationen, Diagramme
    Publisher Oxford University Press
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT020122007
    ISBN 978-0-19-021441-8 ; 9780190214401 ; 0-19-021441-4 ; 0190214406
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

To top